Background: Diabetes type 1 is characterized by the failure of beta cells to produce insulin. Suppressor of cytokine signaling (SOCS) proteins are important regulators of the Janus kinase/signal transducer and activator of transcription (JAK-STAT) pathway. Previous studies have shown that GH can prevent the development of type I diabetes in mice and that SOCS2 deficiency mimics a state of increased GH sensitivity.
Introduction
The suppressor of cytokine signaling (SOCS) protein family consists of eight different proteins (SOCS 1-7 and the cytokine-induced Src-homology 2 (SH2) protein; CIS) [1] . These proteins are intracellular regulators of the cellular sensitivity to extracellular ligands. In particular, ligands activating cytokine receptors that signal through the Janus kinase (JAK)/signal transducer and activator of transcription (STAT) pathway (JAK-STAT) have been connected to SOCS. These receptors include those that bind to leptin, growth hormone (GH), prolactin (PRL), interferon, interleukins and erythropoietin. The SOCS system also interacts with certain tyrosine kinase receptors such as those for insulin, IGF-1 and EGF [2] . SOCS proteins are target recognition subunits of the Cullin2/5-Rbx2 E3 ubiquitin ligases, which transfer ubiquitin to tyrosine-phosphorylated proteins for degradation in either the lysosomes or the proteasomes [3] .
Experimental elimination of different SOCS proteins demonstrates that individual SOCS have distinct functions in the contexts of inflammation, metabolism and growth. The role of different SOCS proteins in diabetes has been the subject for several investigations. Elimination of certain SOCS proteins related to inflammation, e.g. SOCS1, SOCS2 and SOCS3 results in increased inflammatory responses [2] . In addition, SOCS2 knockout (SOCS2 -/-) mice display gigantism due to increased GH sensitivity [4] . Interestingly, none of the diabetogenic features associated with increased circulating GH levels are observed in SOCS2 -/-mice, suggesting that SOCS2 possesses unique actions in the regulation of glucose metabolism. In a recent study, we demonstrated that the elevation of pancreatic insulin content associated with high fat diet is exacerbated in SOCS2 -/-mice, indicating that SOCS2 -/-islets may be protected from high fat-induced stress [5] . An independent study demonstrated that the increase in pancreatic insulin content in response to high fat diet is blunted in islet-specific GHR KO mice, suggesting that an elevated sensitivity to GH signaling in SOCS2 -/-islets may be responsible for the increase in beta cell mass which occurs upon high fat feeding. This pathway is possibly also relevant for the adaptive response of beta cells to physiological situations such as pregnancy, which is associated with elevated levels of GH, PRL and placental lactogen [6, 7] . Given the fact that SOCS2 also modulates inflammatory pathways [8] , it is unknown whether its regulatory actions in the pancreas also upon impact beta cell survival in models of type I diabetes. MLDSTZ partially destroys insulin-producing cells and creates an animal model for type 1 diabetes that survives without insulin treatment [9, 10] . In this study, we tested whether recovery from MLDSTZ is changed in SOCS2 -/-mice, compared to controls.
Materials and methods

Animals
In this study, we have used (SOCS2
) C57BL/6 and SOCS2 -/-mice [11] . All animal studies were carried out in accordance with the principles of laboratory animal care, and with institutional and governmental regulations. The study was carried out in strict accordance with recommendations described in the Guide for the Care and Use of Laboratory Animals issued by the Stockholm North Animal Ethical Committee (Permit Number: N444/11). Mice were housed in a controlled temperature (23 °C) and a 12 h light dark cycle, with free access to water and food. All efforts were made to minimize suffering in experimental animals.
Experimental design
The recovery from MLDSTZ-induced hyperglycemia was studied in 2-and 6-month-old male mice (n = 6 mice per group). SOCS2 -/-and control SOCS2
+/+ mice were injected with five consecutive daily intraperitoneal (ip) injections of STZ (50 mg/kg), according to the experimental scheme shown in a Supplementary Figure 1 . Control mice were injected with physiological saline [12] . Following MLDSTZ treatment, mice were monitored for blood glucose, body weight, food and water intake, glucose tolerance and insulin sensitivity. Food and water consumption were estimated by subtracting the amount of food remaining on the cage grid, or the volume of water within in the bottle from the initial values for food weight or water volume. The food, which was spilled on the cage floor, was not included in these calculations, since spillage was minimal because diet was supplied in pellet form. Mice were considered diabetic when blood glucose levels were > 300 mg/dL at day 9 after the last MLDSTZ injection. Animals were sacrificed by cervical dislocation, and tissues were collected for analysis 65 days after first MLDSTZ injection.
To test for alterations in the tissue sensitivity to PRL and GH, SOCS2 -/-mice were injected with ovine PRL (oPRL) and bovine GH (bGH), respectively, and STAT5 phosphorylation in pancreatic tissues was compared with that in controls. Treated groups received a single ip injection of bGH (1.8 mg/kg) [13] and oPRL (4 mg/kg ip) [14, 15] . Animals were sacrificed by cervical dislocation after 20 min, and tissues collected for further analyses.
Intraperitoneal glucose tolerance test (ipGTT) and intraperitoneal insulin tolerance test (ipITT)
For ipGTT, mice were starved overnight, followed by an ip injection of D-(+)-glucose (20% in 0.9% NaCl) at a dose of 2 g/kg body weight. At different time intervals, blood was collected from the tail and used for measurement of glucose with a glucometer (Roche Diagnostics, Basel, Switzerland). For ipITT, mice were starved for 4 h, and then intraperitoneally injected with either human recombinant insulin (Actrapid, Novo Nordisk, Copenhagen, Denmark) at a dose of 0.75 U/kg body weight, or with saline as a control. Blood glucose levels were determined as described above.
Fluorescence immunohistochemistry
For immunofluorescence staining, frozen pancreas tissue was cryosectioned, and 4 μm sections were allowed to thaw at room temperature before rehydration with PBS for 5 min, fixation with ice-cold acetone for 10 min, and then blocking and permeabilization for 45 min with PBS containing 1.5% (w/v) BSA (VWR, Radnor, USA), 5% (v/v) goat serum (Sigma-Aldrich, St. Louis, MO, USA) and 0.05% (v/v) Triton X-100 (Sigma-Aldrich, St. Louis, MO, USA). After three subsequent washes with PBS, the tissue sections were incubated with primary anti-insulin antibody (ab7842, Abcam, Cambridge, UK) overnight at 4 °C, washed, and then incubated for 1 h at room temperature in the dark with secondary antibody (Alexa Fluor ® 488 goat anti-guinea pig, Life Technologies, Carlsbad, USA). Finally, the slides were washed, mounted with Vectra shield containing DAPI (H-1200, Vector Laboratories, CA, USA) and stored at 4 °C in the dark. Confocal Laser Scanning Microscopy (CLSM) was used to obtain the images (Zeiss, Germany).
Pancreas and plasma insulin content analyses
One third of the pancreatic mass was homogenized in 1 mL acidic ethanol (70% (v/v) ethanol and 37% (v/v) HCl) for insulin quantification per unit weight of pancreas. Insulin extractions were carried out overnight on homogenized pancreas at 4 °C under constant shaking, followed by centrifugation. Resulting supernatants were diluted 1000 times, and insulin was determined using an ELISA kit (Ultrasensitive Rat Insulin ELISA; Crystal Chem, Downers Grov, IL, USA). For plasma insulin, ELISA kits were used to measure plasma insulin (Crystal Chem, Downers Grove, IL, USA).
Western blot analysis
To extract protein for Western blotting, pancreatic tissue samples were washed with ice cold phosphate-buffered saline and homogenized immediately in lysis buffer (50 mM Tris-HCl (pH 7.5), 150 mM NaCl, 1% (v/v) Nonidet ® P40 (Roche Diagnostics), 0.05% (w/v) sodium deoxycholate, 1 mM sodium orthovanadate) at 4 °C. The extracts were centrifuged at 12,000 × g at 4 °C for 10 min, and the protein content of the supernatant was determined by using the Bradford dye-binding method [16] . After a centrifugation step, the supernatant was mixed with Laemmli loading buffer and boiled for 5 min. Proteins were separated using SDS-PAGE, and then transferred to PVDF membranes. As blocking buffer, either 5% (w/v) dry milk or 5% (w/v) bovine serum albumin was used before an overnight incubation at 4 °C with primary antibodies against phosphor-STAT5 and total STAT5 (Cell Signaling, Denver, MA, USA). Next, incubation with horseradish peroxidase-conjugated secondary antibodies (Santa Cruz Biotechnology, CA, USA). Protein bands were visualized by chemiluminescence using the SuperSignal West Pico Chemiluminescent Substrate (Pierce, Thermo Fisher Scientific Inc., Rockford, IL, USA).
Isolation of pancreatic islets
Islets of Langerhans were isolated from SOCS2 -/-and SOCS2 +/+ mice by collagenase digestion in Hank's balanced salt solution (HBSS), followed by sedimentation, as described [17] . Islets were selected under stereomicroscope, and cultured free-floating in RPMI-1640 with 2 mmol/L glutamine, 10% (v/v) FCS, 100 U/mL penicillin, 0.1 mg/mL streptomycin, and 11 mmol/L glucose. Lipotoxicity was induced by using 250-μM palmitate. For hormone treatment, oPRL was used at a
Figure 1: MLDSTZ induces diabetes in 6-month-old SOCS2
+/+ and SOCS2 -/-male mice. (A) Blood glucose was recorded every 3-4 days, starting on day 9 after first injection. (B) Body weight, (C) food intake, and (D) water intake were recorded once a week. Student's t-test analysis between treatment and within genotype: *p < 0.05, **p < 0.001, ***p < 0.0001. Student's t-test analysis between genotype and within treatment: +p < 0.05, ++p < 0.001, +++p < 0.0001. concentration of 200 ng/mL for 72 h at 37 °C in 5% CO 2 . After culture, islets were transferred to Krebs-Ringer bicarbonate (KRB) medium, 10 mmol/L Hepes, 0.2% (w/v) BSA, 2.8 mmol/L glucose and preincubated for 30 min at 37 °C, followed by incubation of 3 groups of 3 islets for 60 min at 37 °C in KRB, containing 2.8 or 16.7 mmol/L glucose. Islets from batch incubations were treated with acid-ethanol to extract cellular insulin. Secreted insulin and islet insulin content were analyzed by RIA using 125 I-labeled insulin and anti-porcine insulin, generated at the Department of Endocrinology, Karolinska Hospital, Stockholm, Sweden.
Statistical analysis
For ipGTT and ipITT, 2-way ANOVA was performed to test for significant differences in the multiple effects of different time points among the 4 mouse groups in each experiment. Student's t-test was used to test for significant differences between two groups. Values of p < 0.05 were considered significant.
Results
Effect of MLDSTZ in 6-month-old SOCS2 -/-mice
Glucose homeostasis and metabolism in 6-month-old SOCS2 -/-was compared to SOCS2 +/+ mice following MLDSTZ treatment. The treatment resulted in elevated plasma glucose values in both groups as soon as 9 days following the start of MLDSTZ injections, whereas vehicle-treated control mice remained normoglycemic ( Figure 1A ). During the course of the study, blood glucose levels in MLDSTZtreated SOCS2 -/-mice were elevated to a lesser extent, compared to those in MLDSTZ SOCS2 +/+ mice ( Figure 1A ). Body weight reduction following MLDSTZ treatment was more marked in SOCS2 +/+ mice, compared to SOCS2 -/-mice ( Figure 1B) , and food and water intake tended to be highest in MLDSTZ-treated SOCS2 +/+ animals ( Figure 1C-D) . In 6-month-old mice, MLDSTZ-treated SOCS2 +/+ mice, there was a clear reduction in the levels of serum insulin that were not observed in SOCS2 -/-mice treated with MLDSTZ ( Figure 2A ). Vehicle-treated SOCS2 -/-mice also exhibited elevated insulin levels, as compared to SOCS2 +/+ mice, indicative of a role for SOCS2 in the regulation of insulin production or secretion. In MLDSTZ-treated SOCS2 +/+ mice, there was an 88% reduction in pancreatic insulin content, whereas the corresponding change in tissue from MLDSTZ-treated SOCS2 -/-mice was only 20% ( Figure 2B ). In this case, no significant differences in insulin content were detected in vehicle-treated SOCS2 +/+ and SOCS2 -/-mice, suggesting the existence of intrinsic -/-mice, compared to treated control mice ( Figure 2C ). Therefore, 6-month-old SOCS2 -/-mice are appear to be protected from the beta cell damage inflicted by MLDSTZ treatment.
In line with the HOMA-IR calculations, the intraperitoneal glucose tolerance test showed a slight elevation in the AUC in vehicle-treated 6-month-old SOCS2 -/-mice, as compared to SOCS2 +/+ control mice. MLDSTZ treatment induced glucose intolerance in both SOCS2
+/+ and SOCS2 -/-mice, although SOCS2 +/+ mice showed a more marked intolerance compared to SOCS2 -/-mice ( Figure 3A and B), confirming a more severe diabetes in MLDSTZ-treated SOCS2 +/+ animals compared to MLDSTZ treated SOCS2 -/-mice. To further study the causes for worsened diabetes in 6-month-old SOCS2 +/+ mice, compared to SOCS2 -/-MLDSTZ-treated mice, we performed ipITT 58 days after the first STZ injection. The insulin sensitivity test was performed after 4 h of fasting, and showed that SOCS2 -/-mice have an improved hypoglycemic response to exogenous insulin, compared to SOCS2 +/+ mice ( Figure 3C  and D) .
Overall these findings demonstrate that 6-month-old SOCS2 -/-mice might be protected from MLDSTZ treatmentinduced diabetes through protective effects on pancreatic beta cells that result in higher levels of plasma insulin and better glucose control.
Effect of MLDSTZ in 2-month-old SOCS2 -/-mice
No significant differences were found in blood glucose levels between 2-month-old MLDSTZ-treated SOCS2
-/-and SOCS2 +/+ mice (Supplementary Figure 2) . These findings suggest an age-dependent effect; since it was further confirmed with ipGTT and ipITT tests that there were no significant differences in glucose tolerance or insulin sensitivity in SOCS2 -/-and SOCS2 +/+ mice of this age (Supplementary Figure 3 ).
Increased Stat5 activation in SOCS2 -/-mice
STAT5a/b are transcription factors that act downstream of the PRL and GH receptors, and have an anti-apoptotic role in beta cells. Therefore, it is possible that the antagonistic effects of SOCS2 on STAT5 activation may contribute to its effect in the beta cells of MLDSTZ-treated mice. In order to test this possibility, SOCS2 -/-mice were injected with a single dose of GH or PRL, and the capacity of these hormones to phosphorylate STAT5 in the pancreas was compared with controls. The data presented in Figure 4A and B show that both GH and PRL increased P-STAT5b protein expression in SOCS2 -/-mice, compared to treated controls. We also analyzed Stat5 protein phosphorylation in isolated islets from SOCS2 +/+ control mice after treatment with oPRL or bGH. As shown in Figure 4C , both cytokines IpITT Curve was normalized to the initial glucose of each group as 100%. *p < 0.05, between treatment within genotype group, +p < 0.05, between genotypes within treatment group; 2-way ANOVA. AUC for ipITT was generated from percentage reduction of plasma glucose after insulin administration. Data are shown as means±SE. Student's t-test analysis between treatment within genotype: *p < 0.05, **p < 0.001, ***p < 0.0001. Student's t-test analysis between genotype within treatment: +p < 0.05, ++p < 0.001, +++p < 0.0001.
induced STAT5 phosphorylation in isolated islets. Overall, these findings suggest that GH-or PRL-mediated activation of STAT5 may protect pancreatic islets from the negative effects of MLDSZT.
β-cells from SOCS2 -/-mice have enhanced insulin secretion
In order to further understand the mechanisms of actions of SOCS2 in relation to beta cell function, we analyzed the insulin secretory capacity of pancreatic islets isolated from SOCS2
+/+ and SOCS2 -/-mice. Islets from SOCS2
-/-pancreas secreted 3.2-fold more insulin than islets from SOCS2 +/+ mice when stimulated with 16.7 mmol/L glucose (n = 6, p < 0.001) ( Figure 5A ). Insulin content and insulin secretion during culture were both significantly higher in islets from SOCS2 -/-mice ( Figure 5B-C) . Insulin secretion remained significantly higher (2.4-fold, p < 0.001) in islets from SOCS2 -/-animals when fractional release (insulin secretion as a percentage of insulin content) was calculated. Similar results were obtained after adjustment for islet protein content or body weight (results not shown).
Additionally, isolated islets were cultured in 11 mmol/L glucose and 0.25% (w/v) BSA±200 μmol/L palmitate±200 ng/mL prolactin for 72 h. This was followed by a pre-incubation in low glucose for 30 min, and final batch incubations for 1 h in 2.8 or 16.7 mmol/L glucose. Plasma glucose levels were significantly lower in SOCS2 -/-than in SOCS2 +/+ animals (6.5±0.3 vs. 7.6±0.3 mmol/L, n = 8, p = 0.045, t-test). Islets in which metabolic stress was induced by culture in the presence of palmitate secreted much less insulin in final batch incubations. When prolactin was present together with palmitate during culture, islets from SOCS2 -/-mice secreted 33% more insulin in the final incubations, compared to SOCS2 +/+ islets.
Discussion
This study shows that SOCS2 plays a role in modulating pancreatic islet beta cell function. SOCS2 knock out animals were less sensitive to diabetes induction by MLDSTZ, compared to SOCS2 expressing controls. Isolated islets from SOCS2 -/-male animals displayed increased levels of glucose-induced insulin secretion and were less sensitive to lipotoxic agents. Lipotoxicity in SOCS2 -/-islets could partly be overcome by addition of PRL. SOCS2 has previously been implicated in the negative regulation of GH and PRL signaling [18] . We previously showed that SOCS2 negatively regulates GH receptor signaling [19] , and that SOCS2 -/-mice grow larger than controls without any elevation in GH levels [20] . These mice are highly sensitive to GH, because SOCS2 deficiency leads to reduced GH receptor degradation, and subsequently increased expression of GH receptor expression [21] . It is well-known that increased levels of GH can lead to insulin resistance [22] , whilst elimination of SOCS2 increases insulin sensitivity. There is a difference between increased hormone levels and increased hormone sensitivity and altered hormone sensitivity because of SOSC2 elimination will change several different intracellular pathways. On the other hand, absence of SOCS2 rescued the failure of lactation and reduction in levels of STAT5 phosphorylation in the mammary gland, both of which are characteristics of PRLR heterozygous knock out mice. In the present study, we found that loss of SOCS2 in pancreatic islets leads to a relative resistance to MLDSTZ. The most likely explanation for these observations is that there is an increase in GH/PRL sensitivity, which occurs through inhibition of GH/PRL receptor breakdown; this leads to the activation of STAT5-triggered signaling pathways, so modulating the response to MLDSTZ. In this study, we do not have a clear hypothesis to explain the increased levels of insulin in the blood of SOCS2 -/-mice. Speculatively, this finding could be related to an inhibitory effect of SOCS2 on insulin secretion [23] , due to interference by SOCS2 with calcium fluxes in beta cells, followed by inhibition of glucose-stimulated insulin secretion. The mechanism underlying how STAT5 activation reduces the effects of MLDSTZ treatment is not fully understood, but it is interesting to note that the expression of a constitutively active form of STAT5 leads to increased beta cell survival following MLDSTZ [24, 25] . It is further relevant to note that beta cells express GH/PRL receptors [26, 27] , and that GH/IGFI signaling has anti-apoptotic effects in beta-cells [28, 29] . Furthermore, the increased beta cell mass observed during pregnancy is assumed to be caused by an increased secretion of placental and pituitary hormones targeting these receptors [30, 31] . Finally, a recent study by Scheinman et al. demonstrated that GH-treated mice had larger islets and higher plasma insulin levels compared to saline treated mice [32] , which is in further support of the hypothesis that GH prevents the development of autoimmune diabetes [33] .
With regards to PRL, Holmstad and Sandler [34] have shown that PRL injections reduce the severity of STZ in mice, whilst other studies have demonstrated the ability of activated STAT5 to protect beta cells from various insults including STZ and lipotoxins [35] . Speculatively, deletion of SOCS2 in beta cells creates a situation similar to pregnancy, characterized by increased PRL/GH stimulation of beta cells that in turn can stimulate STAT5 activity leading to cell proliferation and survival [25, 24] .
However, our study does appear to be at odds with that of Puff et al. [36] , who reported no difference between young male SOCS2 -/-and SOCS2 +/+ animals in terms of their sensitivity to MLDSTZ. Prompted by our findings using 6 month-old mice, we performed a pilot study using younger animals (see Supplementary data), and could confirm the published data of Puff et al. [36] . Therefore, a main finding in the present study is that SOCS2 knock out animals resist MLDSTZ-induced diabetes, but only in older animals. The explanation for why old, but not young, SOCS2
-/-animals are partly protected from MLDSTZ is not known, but it is tempting to speculate that this depends on differences in the endocrine environment between young and old mice. During aging, GH secretion is reduced, resulting in lower GH receptor stimulation [37] . This is likely to happen also in SOCS2 -/-animals, but the increased GH sensitivity present in these animals will biologically circumvent reductions in GH levels that occur during aging.
The connection between SOCS2 and GH signaling has been well described but it should be mentioned that SOCS2 regulates other signaling systems, e.g. IFNα, IFNγ, leukemia inhibitory factor and insulin [38] . Important roles for other SOCS proteins in diabetes have been suggested, and it seems clear that these intracellular regulators affect different key pathways of relevance for diabetes development [39] . For example, it has been shown that elimination of SOCS1 increases the interferon response and potentiates islet cell death [40] . Furthermore, SOCS3 potently protects against type 1 DM through suppressed production of IL-1β and TNFβ in pancreatic beta cells [41, 42] . SOCS3 knock down in beta cells also leads to their resistance to apoptotic cell death caused by STZ [43] . The present data suggest that SOCS2 reduction affects beta cells via improvements in cell survival and functionality. These observations could be of future relevance for diabetes research aiming to improve beta cell functionality.
In conclusion, our data suggest that SOCS2 is a regulator of diabetic states, and that elimination of SOCS2 can have a protective effect in pancreatic beta cells. 
